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ORIGINAL RESEARCH
Identifying At- Risk Patients for Sustained 
Atrial High- Rate Episodes Using the 
C2HEST Score: The West Birmingham Atrial 
Fibrillation Project
Yan- Guang Li , MD, PhD*; Daniele Pastori , MD, PhD*; Kazuo Miyazawa, MD; Farhan Shahid, MD; 
Gregory Y. H. Lip , MD
BACKGROUND: Sustained atrial high- rate episodes (SAHREs) among individuals with a cardiac implantable electronic device 
are associated with an increased risk of adverse outcomes. Risk stratification for the development of SAHREs has never been 
investigated. We aimed to assess the performance of the C2HEST (coronary artery disease or chronic obstructive pulmonary 
disease [1 point each], hypertension [1 point], elderly [age ≥75 years, 2 points], systolic heart failure [2 points], thyroid disease 
[1 point]) score in predicting SAHREs in patients with cardiac implantable electronic devices without atrial fibrillation.
METHODS AND RESULTS: Five Hundred consecutive patients with cardiac implantable electronic devices in the West Birmingham 
Atrial Fibrillation Project in the United Kingdom were followed since the procedure to observe the development of SAHREs, 
defined by atrial high- rate episodes lasting >24 hours. Risk factors and incidence of SAHREs were analyzed. The predictive 
value of the C2HEST score for SAHRE prediction was evaluated. Over a mean follow- up of 53.1 months, 44 (8.8%) patients 
developed SAHREs. SAHREs were associated with higher all- cause mortality (P<0.001) and ischemic stroke (P=0.001). Age 
and heart failure were associated with SAHRE occurrence. The incidence of SAHREs increased by the C2HEST score (39% 
higher risk per point increase). Among patients with a C2HEST score ≥4, the incidence of SAHREs was 3.62% per year (95% 
CI, 2.14– 5.16). The C2HEST score had moderate predictive capability (area under the curve, 0.73; 95% CI, 0.64– 0.81) and 
discriminative ability (log- rank P=0.003), which was better than other clinical scores (CHA2DS2- VASc, CHADS2, HATCH).
CONCLUSIONS: The C2HEST score predicted SAHRE incidence in patients without atrial fibrillation who had an cardiac implant-
able electronic device, with the highest risk seen in patients with a C2HEST score ≥4 The benefit of using the C2HEST score 
in clinical practice in this patient population needs further investigation.
Key Words: atrial high rate episode ■ C2HEST score ■ risk evaluation ■ subclinical atrial fibrillation
Atrial high- rate episodes (AHREs) are common among patients with cardiac implantable elec-tronic devices (CIEDs), with a prevalence ranging 
from 30%1 to 70%.2 In patients without atrial fibrillation 
(AF), the prevalence of AHREs is ≈30%.3,4 Patients with 
AHREs are at significantly increased risk of developing 
overt AF, and, for this reason, AHREs are regarded to 
as “subclinical AF.” Indeed, AHRE represents a signif-
icant clinical entity, with the increasing application of 
CIED and its detection of infrequent atrial arrhythmias 
through continuous long- term heart rhythm monitoring.
The occurrence of an AHRE has been associ-
ated with an adverse clinical prognosis,2 including 
increased thromboembolism (hazard ratio [HR], 3.40; 
95% CI, 1.38– 8.37), mortality (HR, 3.47; 95% CI, 1.51– 
7.95),5,6 and heart failure (HF) (HR, 4.58; 95% CI, 1.64– 
12.8).7 The minimum duration of AHRE conferring 
increased thromboembolic risk is not well defined, 
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but there is a growing evidence showing that sus-
tained AHRE (SAHRE) lasting >24 hours is associated 
with an increased risk of thromboembolic events.5,8,9 
In a subanalysis from the ASSERT (Asymptomatic 
Atrial Fibrillation and Stroke Evaluation in Pacemaker 
Patients and the Atrial Fibrillation Reduction Atrial 
Pacing Trial),5 SAHRE was associated with significantly 
increased risk of subsequent stroke or systemic em-
bolism (HR, 3.24; 95% CI, 1.51– 6.95), while no signif-
icant risk difference was observed between patients 
with AHRE of 6 minutes to 24 hours or those without 
AHRE.5 Similarly, Capucci et al8 reported that only AF 
episodes lasting >24 hours were independently related 
with embolism (odds ratio, 3.1; 95% CI, 1.1– 10.5). Cori 
et al9 also showed that AF/AHREs lasting >24 hours 
confers a critical higher thromboembolic risk (>4.1% 
per year) compared with those AF/AHREs lasting 
<24 hours (<1.68% per year). These results show that 
there may be a dose- effect relationship between AHRE 
and thromboembolism, implying that SAHRE warrants 
more clinical considerations.
For these reasons, a consensus document from the 
European Heart Rhythm Association10 warranted an 
early detection of patients with SAHRE through care-
ful examination of intracardiac electrograms. This may 
allow prompt detection of AF and timely initiation of an-
ticoagulation, thus reducing the risk of stroke. In a retro-
spective study including 4388 patients with new- onset 
AF, 98 strokes (2.2%) occurred between AF diagnosis 
and oral anticoagulation (OAC) initiation.11 Thus, early 
detection of AF and early initiation of anticoagulation is 
crucial for avoiding strokes. In a retrospective study in-
cluding 71 CIEDs patients with previous transient isch-
emic attack (TIA)/stroke, intensive remote monitoring 
was associated with reduced risks of all- cause mortality 
(2.2% per year versus 8.1% per year) and hospitalization 
(5.8% per year versus 9.7% per year).12
There is still a lack of evidence on which group of 
patients with CIEDs may benefit from more intensive 
device evaluation or continuous remote monitoring 
regarding AF detection. We have previously demon-
strated that some clinical conditions and laboratory 
biomarkers are associated with the development of 
AHRE.13 However, no risk evaluation model for the de-
velopment of SAHRE has been developed.
Recently, a new clinical risk evaluation, the C2HEST 
(coronary artery disease or chronic obstructive pulmo-
nary disease [1 point each], hypertension [1 point], el-
derly [age ≥75 years, 2 points], systolic HF [2 points], 
thyroid disease [1 point]) score, has been developed 
and validated to predict incident AF.14 The C2HEST 
score has been validated in diverse populations with 
modest to moderate predictive capability.15– 19 SAHRE 
has been recognized as “subclinical AF” and shares 
many common characteristics and risk factors with 
clinical AF. In this study, we investigated the hypoth-
esis of whether the C2HEST score was suitable in as-
sessing the risk of developing SAHRE in patients with 
a CIED and no history of AF.
CLINICAL PERSPECTIVE
What Is New?
• Sustained atrial high- rate episodes in patients 
with cardiac implantable electronic device are 
common, with age and heart failure being inde-
pendent risk factors.
• The risk of sustained atrial high- rate episodes 
can be stratified by the C2HEST (coronary ar-
tery disease or chronic obstructive pulmonary 
disease [1 point each], hypertension [1 point], 
elderly [age ≥75 years, 2 points], systolic heart 
failure [2 points], thyroid disease [1 point]) score 
with moderate predictive accuracy.
What Are the Clinical Implications?
• For high- risk patients (C2HEST score ≥4), a more 
intensive (eg, shorter follow- up interval) or con-
tinuous (eg, remote monitoring) device interview 
may be needed, enabling early detection and 
early treatment of subclinical atrial fibrillation.
Nonstandard Abbreviations and Acronyms
AHRE atrial high- rate episode
C2HEST coronary artery disease or 
chronic obstructive pulmonary 
disease (1 point each), 
hypertension (1 point), elderly 
(age ≥75 years, 2 points), 
systolic heart failure (2 points), 
thyroid disease (1 point)
CHADS2 congestive heart failure, 
hypertension, age ≥75 years, 
diabetes mellitus, stroke or 
transient ischemic attack
CHA2DS2- VASc congestive heart failure, 
hypertension, age ≥75 years, 
diabetes mellitus, stroke or 
transient ischemic attack, 
vascular disease, age 65 to 74 
years, sex category
HATCH hypertension, age ≥75 years, 
transient ischemic attack or 
stroke, chronic obstructive 
pulmonary disease, and heart 
failure
OAC oral anticoagulation
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METHODS
The data that support the findings of this study 
are available from the corresponding author upon 
reasonable request. The data set of patients with 
CIEDs, which belongs to the West Birmingham Atrial 
Fibrillation Project, has been previously described.6,13 
Consecutive patients who have attended the cardiol-
ogy department of Sandwell and West Birmingham 
Hospitals between January 1999 to January 2017 
were retrospectively reviewed. All patients with a 
permanent pacemaker, implantable cardioverter- 
defibrillator, or cardiac resynchronization therapy de-
vice were followed since the implantation procedure. 
Patients’ information was collected from the Clinical 
Data Archive of the National Health System. Patients 
with known AF at baseline were excluded from the 
analysis, considering it has a significant impact on 
the incidence of SAHRE. The ascertainment of previ-
ous AF was majorly based on medical history. For 
patients receiving anticoagulation and antiarrhyth-
mics at baseline, the indications for such medica-
tions were also checked to ensure that they were not 
being prescribed for known previous AF. Conditions 
regarding AF presence and laboratory and echocar-
diography data were limited within 1 year before pa-
tient inclusion of the current study.
AHRE was defined as an atrial rate ≥175 beats 
per minute, and SAHRE was defined as a single 
AHRE lasting >24 hours. The identification and du-
ration of AHRE events were automatically recorded 
by each device. The records of AHRE events were 
reviewed by arrhythmia specialists in charge of de-
vice follow- up and uploaded to local websites of an 
individual device company. Baseline demographic 
characteristics, medical histories, medications, 
echocardiography, and laboratory test results were 
entered into a uniformed data framework, which 
was conducted by 3 independent investigators (D.P., 
K.M., and Y.G.L). Data collection and secondary ver-
ification were also performed to guarantee quality 
and accuracy. C2HEST; CHA2DS2- VASc (congestive 
HF, hypertension, age ≥75 years, diabetes mellitus, 
stroke or TIA, vascular disease, age 65 to 74 years, 
sex category); CHADS2 (congestive HF, hypertension, 
age ≥75 years, diabetes mellitus, stroke or transient 
ischemic attack); and HATCH (hypertension, age ≥75 
years, TIA or stroke, chronic obstructive pulmonary 
disease, and HF) scores were calculated according 
to their original descriptions.14,20,21
This study was conducted in accordance with the 
European Union Guidance on Good Clinical Practice 
CPMP/ECH/135/95 and the Declaration of Helsinki. 
Patients were not involved in data extraction, and 
there was no impact on their medical/social care. 
Ethical review was therefore not required with our 
use of anonymized data, and patient consent was 
not sought.
Statistical Analysis
Continuous and categorical variables were expressed 
as mean±SD, median (interquartile range), or ob-
served numbers (percentages), wherever appropriate. 
Differences between groups were tested using Student 
t test (normally distributed variable), Mann- Whitney U 
test (non- normal distributed data), and chi- square test 
(categorical variable). Patients were grouped accord-
ing to C2HEST score as per the original article (low 
risk: 0 or 1 point, medium risk: 2 or 3 points, high risk: 
≥4 points). The incident rate and 95% CIs of patients 
with and without SAHRE ≥24 hours were calculated. 
Kaplan- Meier curves were used to depict the accu-
mulative hazard of patients developing SAHRE. For 
depicting Kaplan- Meier curves, only the first recorded 
SAHRE at follow- up was taken into account for the 
outcome event. The difference between Kaplan- Meier 
curves among the 3 groups was analyzed using log- 
rank test. The HRs and 95% CIs of patients with dif-
ferent risk categories were assessed using a Cox 
proportional hazard model. Potential predictive factors 
of SAHRE in the univariable analysis with P<0.1 were 
included in the multivariable model. For assessment of 
the discriminative performance of the C2HEST score 
in predicting SAHRE, receiver operating characteristic 
curve analysis and Delong test were performed.
We built 2 different survival models: model 1, which 
included all significant risk factors at multivariable Cox 
proportional hazards regression analysis; and model 
2, which included the same factors of model 1 plus 
the C2HEST score. The performances of the 2 mod-
els were then compared. Goodness- of- fit test was 
conducted using Hosmer- Lemeshow test, which de-
scribes the difference between expected (by score) 
and observed number of events.
Given the underlying influence of antiarrhythmic 
drugs on SAHRE, sensitivity analysis with receiver op-
erating characteristic curves and Kaplan- Meier curves 
(log- rank test) were conducted among individuals not 
taking antiarrhythmic drugs (amiodarone, β- blockers, 
and digoxin). We also tested the performance of the 
C2HEST score in predicting short- term AHRE (≥5 min-
utes). A 2- tailed P value <0.05 was considered sta-
tistically significant. Analyses were performed using 
SPSS Statistics version 23.0 (IBM), STATA software 
version 15.0 (StataCorp LLC), and MedCalc software 
version 18.11 (MedCalc Software Ltd).
RESULTS
The baseline characteristics of the studied popula-
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Table 1. Baseline Characteristics of the Patients
Characteristics Total (N=500) No SAHRE (n=456) SAHRE (n=44) P Value
Men, n (%) 285 (57.0) 252 (55.3) 33 (75.0) 0.012
Age, mean±SD 69.9±14.6 69.3±14.9 75.6±9.3 <0.001
Age ≥65 y, n (%) 356 (71.2) 315 (69.1) 41 (93.2) 0.001
Age ≥75 y, n (%) 233 (46.6) 205 (45.0) 28 (63.6) 0.018
Comorbidities, n (%)
Hypertension 351 (70.2) 316 (69.3) 35 (79.5) 0.156
DM 135 (27.0) 120 (26.3) 15 (34.1) 0.268
Hyperlipidemia 293 (58.6) 261 (57.2) 32 (72.7) 0.145
CAD 134 (26.8) 117 (25.7) 17 (38.6) 0.064
Stroke/TIA 50 (10.0) 44 (9.6) 6 (13.6) 0.400
COPD 22 (4.4) 20 (4.4) 2 (4.5) 0.961
HF 15 (3.0) 11 (2.4) 4 (9.1) 0.013
Hyperthyroidism 6 (1.2) 4 (0.9) 2 (4.5) 0.033
Device type, n (%)
PPM 472 (94.4) 431 (94.5) 41 (93.2) 0.713
ICD 22 (4.4) 19 (4.2) 3 (6.9) 0.413
CRT 6 (1.2) 6 (1.3) 0 (0.0) 0.444
Indications for device implantation, n (%)
Sick sinus syndrome 124 (24.8) 115 (25.2) 9 (20.5) 0.545
Atrioventricular block 281 (56.2) 254 (55.7) 27 (61.4) 0.908
Syncope 43 (8.6) 41 (9.0) 2 (4.5) 0.337
HF 4 (0.8) 4 (0.9) 0 (0.0) 0.534
VT/VF 22 (4.4) 19 (4.2) 3 (6.8) 0.423
Laboratory results
eGFR, mL/min per 1.73 m2 69.4±22.4 69.8±22.3 65.6±23.7 0.201
Creatinine, µmol/L 94.3±39.5 93.6±39.8 101.7±35.8 0.240
White blood cell count 
(×109/L)
7.90±5.01 7.75±2.40 9.52±15.1 <0.001
Echocardiography
LAD, mm 41.1±8.7 40.5±8.4 45.9±10.4 0.021
LAV, mL 54.4±23.5 52.2±20.6 71.0±35.3 0.011
LAVI, mL/m2 30.3±13.0 29.1±11.0 39.5±21.0 0.015
LVEF (%) 57.4±14.0 58.0±13.8 52.9±15.4 0.076
Medication, n (%)
β- Blocker 87 (17.4) 78 (17.1) 9 (20.5) 0.852
Digoxin 6 (1.2) 5 (1.1) 1 (2.3) 0.567
Amiodarone 17 (3.4) 15 (3.3) 2 (4.5) 0.777
Diuretic 114 (22.8) 102 (22.4) 12 (27.3) 0.743
Statin 270 (62.5) 237 (52.0) 33 (75.0) 0.024
CCB 124 (24.8) 113 (24.8) 11 (25.0) 0.698
Anticoagulant 34 (6.8) 27 (5.9) 7 (16.0) 0.030
Antiplatelet 224 (44.8) 202 (44.3) 22 (50.0) 0.942
ACEI/ARB 212 (42.4) 185 (40.6) 27 (61.4) 0.040
CHA2DS2- VASc 3.1±1.7 3.0±1.7 3.7±1.5 0.009
ACEI indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; 
CHA2DS2- VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 
74 years, sex category; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DM, diabetes mellitus; eGFR, estimated 
glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter- defibrillator; LAD, left atrium diameter; LAV, left atrial volume; LAVI, left atrial volume 
index; LVEF, left ventricular ejection fraction; PPM, permanent pacemaker; SAHRE, sustained atrial high- rate episode; TIA, transient ischemic attack; VF, 
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known AF at baseline, 500 patients with CIEDs were 
included in the present study. A permanent pace-
maker was the most frequently used device (94.3%), 
followed by implantable cardioverter- defibrillator (4.4%) 
and cardiac resynchronization therapy (1.2%). The 
most prevalent reasons for device implantation were 
atrioventricular block (56.2%) and sick sinus syn-
drome (24.8%). The mean age of the population was 
69.9  years, of which 57.0% were men. Hypertension 
(70.2%), hyperlipidemia (58.6%), and diabetes mel-
litus (27.0%) were the most prevalent comorbidities. 
For patients receiving anticoagulation, the indications 
included previous pulmonary embolism, deep venous 
thrombosis, and hip replacement (n=34 in total). In 
addition, 87 patients (78 in the SAHRE group and 9 
in the non- SAHRE group) were taking β- blockers for 
hypertension, HF, or coronary artery disease rather 
than arrhythmias. Six patients were taking digoxin for 
HF, and 17 were taking amiodarone for ventricular ar-
rhythmias. In the 17 patients who were treated with 
amiodarone, 9 were implanted with an implantable 
cardioverter- defibrillator, 1 with a cardiac resynchroni-
zation therapy device, and 7 had permanent pacemak-
ers. Among patients with HF, HF with reduced ejection 
fraction was the predominant type and only 2 patients 
had HF with preserved ejection fraction, which was 
recognized as those with symptoms or physical signs 
of HF and with left ventricular ejection fraction >50% 
on echocardiography.
SAHRE Incidence and Risk Factors
During a mean follow- up of 53.1  months (SD=33.9) 
(SAHRE group: 51.8  months [SD=34.0]; non- SAHRE 
group: 66.7  months [SD=29.7]), 168 patients had 
an AHRE (>5  minutes), among which 44 developed 
SAHREs (>24  hours), with an incident rate of 2.09% 
per year (95% CI, 1.47%– 2.71% per year). Patients 
with SAHREs were more frequently men, older, and 
more likely to have hyperthyroidism and HF (P<0.05, 
respectively). Larger left atrium diameter, left atrium 
volume, and left atrium volume index were observed 
in patients with SAHRE (P<0.05, respectively). Patients 
with SAHREs had significantly higher CHA2DS2- 
VASc scores, with 95.5% (n=42) of patients having a 
CHA2DS2- VASc score ≥2 (men) or 3 (women) com-
pared with 78.3% (n=357) patients without SAHREs 
(P=0.007) (Table 1).
In univariable Cox proportional hazard regression 
analysis, male sex, age ≥75 years, HF, and white blood 
cell counts were associated with SAHREs (Table 2). In 
adjusted modeling, male sex, age ≥75 years, HF, and 
white blood cell count were independently associated 
with SAHREs (Table 2). In the multivariable model anal-
ysis, age ≥75 years and HF were the 2 strongest risk 
factors (Table 2).
C2HEST Score and Risk of SAHRE
The mean C2HEST score was 2.5±1.6. Patients with 
SAHREs had a significantly higher mean C2HEST 
score compared with those without SAHREs (3.4±1.5 
versus 2.4±1.6, respectively; P<0.001). Patients were 
categorized into 3 groups according to C2HEST score 
risk, ie, low- risk: 0 or 1 point (28.8%, n=144), medium 
risk: 2 or 3 points (42.2%, n=211), and high risk: ≥4 
points (29.0%, n=145) (Table  3). The follow- up dura-
tions were 50.9±32.5 months, 53.9±37.2 months, and 
54.1±30.3 months for the low- , medium- , and high- risk 
groups, respectively. The risk of SAHREs increased 
Table 2. Risk Factors Associated With the Development of SAHRE
Characteristics
Univariable Analysis Multivariable Analysis
Univariable AUC Adjusted AUCHR 95% CI P Value HR 95% CI P Value
Men 2.14 1.08– 4.23 0.029 0.53 1.04– 4.17 0.039 0.60 0.53
Age ≥75 y 2.93 1.57– 5.45 0.001 0.55 1.36– 4.84 0.004 0.66 0.55
Hyperthyroidism 1.00 0.53– 1.89 0.998
COPD 0.82 0.20– 3.39 0.783
Hypertension 1.67 0.80– 3.47 0.170
DM 1.65 0.88– 3.08 0.117
HF 4.02 1.43– 11.26 0.008 3.02 1.06– 8.57 0.038 0.54 0.63
Stroke/TIA 1.87 0.79– 4.46 0.156
Vascular disease 1.55 0.85– 2.83 0.158
CAD 1.46 0.79– 2.69 0.223
WBC 1.04 1.02– 1.07 0.001 1.04 1.01– 1.06 0.005 0.51 0.51
LAD 1.33 0.85– 2.09 0.209
eGFR 0.99 0.98– 1.00 0.166
AUC indicates area under the curve; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated 
glomerular filtration rate; HF, heart failure; HR, hazard ratio; LAD, left atrial dimension; SAHRE, sustained atrial high- rate episode; TIA, transient ischemic attack; 
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by the C2HEST score (Table  3). Using patients with 
C2HEST score 0 or 1 as the reference group, the HR 
for the risk of SAHREs increased in the medium- and 
high- risk groups (Table 3). For each point increase of 
the C2HEST score, there was a 39% higher risk of de-
veloping SAHREs (HR, 1.39; 95% CI, 1.16– 1.68).
As depicted by the survival curve, patients with a 
C2HEST score ≥4 showed a higher risk for SAHRE 
development compared with those in the low- and 
medium- risk groups (log- rank test, P=0.003) (Figure 1). 
No difference was found between the low- and 
medium- risk groups (P=0.159). When we divided pa-
tients into 2 groups, such as high risk (C2HEST ≥4) and 
low- medium risk (C2HEST score 0– 3), we found a sig-
nificant difference in the incidence of SAHRE (IR 3.62% 
per year versus 1.47% per year; log- rank, P=0.001).
The C2HEST score showed moderate predicting ac-
curacy for SAHREs with an area under the curve (AUC) 
of 0.73 (95% CI, 0.64– 0.81). The test for goodness- of- 
fit was not significant (P=0.931).
Model 1 (including sex, age, HF, and white blood 
cell count) had an AUC of 0.66 (95% CI, 0.57– 0.69) 
and model 2 (including sex, age, HF, white blood cell 
count, and C2HEST) showed an AUC of 0.74 (95% CI, 
0.64– 0.79), which was superior to model 1 (P=0.033).
Secondary Analyses
Among patients with a history of ischemic stroke/TIA, 
SAHRE showed better predictive capability (AUC=0.77; 
95% CI, 0.58– 0.95). Among patients with a permanent 
pacemaker, the AUC for the C2HEST score was 0.70 
(95% CI, 0.62– 0.77).
Table 3. Risk of SAHRE According to the C2HEST Score Groups
C2HEST Score Patients, n (%) SAHRE, n
Incident Rate* 
(95% CI) HR (95% CI) P Value
0 or 1 144 (28.5) 5 0.85 (0.27– 1.94) Reference Reference
2 or 3 211 (42.2) 17 1.87 (1.06– 2.91) 2.06 (0.76– 5.59) 0.159
≥4 145 (29.0) 22 3.62 (2.14– 5.16) 4.25 (1.61– 11.22) 0.004
C2HEST indicates coronary artery disease or chronic obstructive pulmonary disease (1 point each), hypertension (1 point), elderly (age ≥75 years, 2 points), 
systolic heart failure (2 points), thyroid disease (1 point); HR, hazard ratio; and SAHRE, sustained atrial high- rate episode.
*Per 100 patient- years (crude rate).
Figure 1. The cumulative survival rates of sustained atrial high- rate episodes (SAHREs) with 
regard to the C2HEST (coronary artery disease or chronic obstructive pulmonary disease [1 point 
each], hypertension [1 point], elderly [age ≥75 years, 2 points], systolic heart failure [2 points], 
thyroid disease [1 point]) score.
Kaplan- Meier curves depict the different accumulative survival rates free from SAHRE regarding C2HEST 
score risk groups. A significant higher hazard is seen among the high- risk subgroup compared with the 
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We compared the C2HEST score with other scor-
ing systems such as CHA2DS2- VASc, CHADS2, and 
the HATCH. We found that the C2HEST score showed 
a better predictive of SAHRE (versus CHA2DS2- VASc 
0.67 [0.58– 0.76], P=0.128; CHADS2 0.68 [0.58– 0.78], 
P=0.307; and HATCH 0.67 [0.58– 0.76], P=0.089) 
(Figure 2).
We also tested the risk stratification capacity of the 
C2HEST score for the AHREs ≥5 minutes. The prev-
alence of AHREs ≥5 minutes increased with C2HEST 
risk groups (24.3%, 31.8%, and 45.5% for the low- , 
medium– , and high- risk groups, respectively; log- 
rank P=0.001, figure not shown). The risk of AHRE 
increased by 23.8% for each 1- point increase in the 
C2HEST score.
SAHRE and Clinical Outcomes
During follow- up, thromboembolic events were found 
in 27 (5.4%) patients, 30 (6.0%) experienced acute HF, 
10 (2.0%) were hospitalized for cardiovascular reasons, 
and 28 (5.8%) died. Major bleeding was seen in 9 (1.8%) 
patients and minor bleeding in 25 (5.5%) patients.
Patients who developed SAHREs had significantly 
higher risks of all- cause death (4.1% per year versus 
1.0% per year, P<0.001) and ischemic stroke (5.3% 
per year versus 4.2% per year, P=0.001). Patients with 
SAHREs were older and were more likely male and 
with HF. No significant differences were seen between 
patients with and without SAHREs regarding myocar-
dial infarction, acute HF, bleeding, and cardiovascular 
hospitalization (P>0.05, respectively).
Among the 44 patients who developed SAHREs at 
follow- up, 7 patients were taking OAC at baseline, be-
cause of previous embolic events, including pulmonary 
embolism or deep vein thrombosis; and 23 patients 
were prescribed an OAC agent after the develop-
ment of AHRE. The mean time interval between the 
date of AHRE development to OAC prescription was 
573  days, implying a probable delayed treatment of 
subclinical AF. Among the 23 patients, 3 were started 
with an OAC agent after embolic events (2 ischemic 
strokes and 1 systemic embolism).
DISCUSSION
Our study suggests that the C2HEST score has mod-
erate predictive accuracy for SAHRE in patients im-
planted with a CIED and without a history of AF. The 
risk of SAHRE gradually increased by the C2HEST 
score. Furthermore, we confirm that SAHRE was as-
sociated with worse clinical outcomes, including all- 
cause mortality and ischemic stroke.
Only a few studies have focused on the risk fac-
tors for AHREs lasting >5 or 6 minutes.22,23 However, 
SAHREs lasting >24 hours are more likely to represent 
a “subclinical” AF condition, needing proactive man-
agement given its association with thromboembolic 
events and mortality. In the present study, we found 
that age and HF were the most significant risk factors 
for SAHREs, which is similar to that of the risk factors 
for incident AF.14,18,24
In the ASSERT trial, 10.7% of patients developed 
SAHREs during 2.5 years of follow- up,5 with an esti-
mated incidence of ≈4.3% per year. All of those enrolled 
patients were older than 65  years with hypertension 
and an enlarged left atrium at baseline. In the present 
study, we found a prevalence of SAHRE of 8.8% with 
an incident rate of 2.09% per year, which is lower than 
in the ASSERT study, probably related to a relatively 
younger population (70 versus 76 years).
To identify patients at risk of SAHREs we used the 
C2HEST score, primarily designed for incident AF.
14 
The C2HEST score showed moderate ability in as-
sessing the individual risk for SAHRE development 
(AUC=0.728), which was consistent in other critical 
subgroups of patients, such as those with a history of 
ischemic stroke/TIA. The incident rate of SAHRE in-
creased by the C2HEST score, with a 39% higher risk 
for SAHRE for each point increase of the score. In 
Figure 2. Performance of the risk scores for predicting 
sustained atrial high- rate episodes.
C2HEST indicates coronary artery disease or chronic obstructive 
pulmonary disease (1 point each), hypertension (1 point), elderly 
(age ≥75 years, 2 points), systolic heart failure (2 points), thyroid 
disease (1 point); CHADS2, congestive heart failure, hypertension, 
age ≥75 years, diabetes mellitus, stroke or transient ischemic 
attack; CHA2DS2- VASc, congestive heart failure, hypertension, 
age ≥75 years, diabetes mellitus, stroke or transient ischemic 
attack, vascular disease, age 65 to 74 years, sex category; and 
HATCH, hypertension, age ≥75 years, transient ischemic attack 
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particular, among patients with a C2HEST score ≥4, 
nearly 1 in 6 developed SAHREs during follow- up, 
which may enable clinicians to flag those patients who 
warrant more intense device review or continuous re-
mote monitoring. Close monitoring (eg, ≤3  months) 
of patients with a C2HEST score ≥4 would help in 
identifying patients who develop SAHREs earlier than 
“routine” follow- up, eg 6 or 12 months. Furthermore, 
remote monitoring could be more effective in iden-
tifying SAHREs, as shown by the CRYSTAL AF 
(Cryptogenic Stroke and Underlying AF) study, in 
which remote monitoring identified significantly more 
patients with AHREs within 6 months compared with 
standard follow- up (8.9% versus 1.4%; HR, 6.4 [95% 
CI, 1.9– 21.7]).25 Indeed, compared with standard 
scheduled device follow- up, remote monitoring could 
detect AF/AHRE 1 to 5 months earlier.26 Concerning 
cost- effectiveness, remote monitoring might even be 
more precisely applied to at- risk patients for SAHRE 
(C2HEST score ≥4), waiving the need to monitor 
non– high- risk patient groups, which needs further 
investigation.
Nevertheless, many issues regarding AHRE are 
not definitive, including lack of a temporal relation-
ship between AHREs and thromboembolic events.27 
Current evidence in the literature does not support 
routine anticoagulation of SAHREs if there is no clin-
ical overt AF being diagnosed, given that we still do 
not know whether the embolic risk could be mitigated 
or prevented by anticoagulation, and whether the in-
creased risk of bleeding is acceptable. The efficacy 
and safety of OAC for stroke prevention in AHREs is 
under investigation (the ARTESiA [Apixaban for the 
Reduction of Thrombo- Embolism in Patients With 
Device- Detected Sub- Clinical Atrial Fibrillation]28 
and NOAH- AFNET 6 [Non– vitamin K Antagonist 
Oral Anticoagulants in Patients With Atrial High Rate 
Episodes]29 trials).
We also compared the C2HEST score with other 
clinical risk scores such as the CHADS2, CHA2DS2- 
VASc, and HATCH scores. The predictive value of the 
C2HEST score was similar to CHADS2 and CHA2DS2- 
VASc and slightly better than the HATCH score. 
However, these scores were proposed to predict 
stroke in AF (CHADS2 and CHA2DS2- VASc) and AF 
progression (HATCH), and not for predicting incident 
AF or AHRE. A recent EHRA consensus document 
appealed for using the appropriate risk score for what 
they were proposed for, and not to use scores to pre-
dict outcomes for which they were not designed.30
In the present study, we found that SAHRE was 
associated with a significantly increased risk of all- 
cause mortality and stroke, which is similar to a re-
cent study showing that patients with SAHREs had a 
higher risk of mortality (HR, 2.67).31 Previously, we have 
shown that AHRE was related to higher major adverse 
cardiovascular events.32 Altogether these findings sug-
gest that the occurrence of AHREs may worsen the 
prognosis of patients.
Strengths and Limitations
We have demonstrated that SAHRE is not uncommon 
among patients with CIEDs. A high- risk subgroup of 
patients for SAHRE could be identified through a scor-
ing system, namely the C2HEST score. This study also 
represents the first application of the C2HEST score for 
predicting SAHRE. The C2HEST score is a user- friendly 
score that may allow better risk stratification in this pa-
tient population.
Nevertheless, there are some limitations in the 
present study. This is a retrospective study with a rel-
atively limited sample size, claiming for a validation in 
larger population studies. Although a single episode 
of AHRE lasting >24 hours was defined as an SAHRE, 
there is a certain variability for its definition. Thus, 
an atrial rate ranging from 170  beats per minute to 
200 beats per minute has been used in previous stud-
ies. We have used the most frequently used and reli-
able criteria (from the device programming aspect) to 
define AHRE, which may have a slight difference com-
pared with other cutoff values. The performance of the 
C2HEST score may vary in populations with a different 
incidence of chronic obstructive pulmonary disease 
and thyroid diseases. Of note, these 2 conditions may 
be underdiagnosed in clinical practice; our study sug-
gests that physicians managing patients with CIEDs 
should make efforts in detecting these 2 comorbidi-
ties to better stratify the risk of SAHREs. Although the 
study applied a long- term follow- up of real- world data, 
the results need to be confirmed in larger, prospective, 
multicenter studies. Although our data indicate a po-
tential benefit of intensive monitoring or follow- up for 
patients with CIEDs who have a high risk of developing 
SAHREs, the absolute benefit of applying this strategy 
in improving AF detection and reducing stroke needs 
to be addressed in future studies.
CONCLUSIONS
Individual risk of SAHREs could be stratified using 
the C2HEST score with moderate accuracy and dis-
criminative ability. Patients with CIEDs who have a 
high risk of developing SAHREs, such as those with 
C2HEST score ≥4, might benefit from a more inten-
sive device examination or continuous remote moni-
toring, which would need to be tested in prospective 
studies.
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